Ultragenyx Pharmaceutical (RARE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities maintained a Buy rating on the stock and has a $83.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tazeen Ahmad has given his Buy rating due to a combination of factors including the promising clinical data from Ultragenyx Pharmaceutical’s UX111 treatment for Sanfilippo syndrome type A. The treatment showed significant improvement in cognitive function, with a noteworthy reduction in toxic cerebrospinal fluid heparan sulfate levels and a positive impact on all Bayley-III cognitive subdomains.
Additionally, the company reported meaningful retention of functional abilities in older patients outside the main treatment group, reinforcing UX111’s clinical efficacy. With a regulatory decision expected in the second half of 2025 and a strong late-stage pipeline, Ultragenyx is positioned as a top pick for 2025 with multiple opportunities for commercialization. The safety profile of UX111 remains consistent with other AAV gene therapies, further supporting the Buy recommendation and a price objective of $83.
RARE’s price has also changed slightly for the past six months – from $49.080 to $45.370, which is a -7.56% drop .